Abstract:ID 93978 Poster Board 520 Altered dopamine signaling in the central nervous system (CNS) has been the subject of many studies, as it has become a fundamental feature of numerous CNS diseases and disorders, including Parkinson's disease (PD) and substance use disorder (SUD). The dopamine transporter (DAT) is the primary regulator of dopamine (DA) signaling in the central nervous system (CNS) and in the periphery. This member of the re-uptake-1 monoamine transporters (MATs) clears extracellular dopamine by transporting it into the cell for storage. Recent studies have shown that peripheral immune cells such as monocytes and macrophages express DAT and the norepinephrine transporter (NET), and that DAT regulates innate immune response. Alterations of DAT in the CNS impacts the expression of this protein in peripheral immune cells affecting immune regulation. Development of methodologies and tools that will facilitate our understanding of the mechanism underlying these observations can facilitate strategies to study DAT-associated disease and disorders in the periphery. Fluorescently labelled ligands (FLL) have proven useful as tools to study protein expression, localization, and distribution and downstream processes in distinct live cell systems, opening a venue to study endogenously expressed proteins. In this work, we set out to develop a high affinity and selective FLL for the detection of DAT in peripheral blood mononuclear cells (PBMCs) by flow cytometry. For our synthetic design, we identified two atypical DAT inhibitors, JJC8-087 and JJC8-089, as parent ligands. These compounds bind with high affinity to DAT and selectivity over SERT and NET. Fluorescent labelling of the parent ligand was based on previously reported structure-activity relationship studies. Binding affinities of all final compounds for rDAT, rSERT and rNET were obtained via radioligand binding assay in Sprague-Dawley rat brain tissue and hDAT-HEK293 cell membranes. PBMCs were isolated from whole blood via density media centrifugation and samples treated with either the FLL or a control antibody were analyzed via flow cytometry on a 5-laser Cytek Aurora Spectral Cytometer. Probes based on JJC8-087 demonstrated the highest DAT affinity and were selective with respect to SERT and NET. The lead DiSulfoCy5 FLL, GC04-38 (rDAT K i = 159 nM) was ~26-fold rDAT selective over rSERT ( K i = 4.2 mM) and >63-fold selective over rNET ( K i = >10 mM), in addition, a similar binding affinity for hDAT was obtained ( K i = 191 nM). GC04-38 was used to label DAT in both mouse and human peripheral blood mononuclear cells (PBMCs) and analyzed via flow cytometry revealing comparable results with a control DAT antibody, reducing the time of sample preparation from 165 minutes (antibody control) to 30 min (FLL). We validated the selective detection of DAT with PBMCs isolated from a DAT knockout mouse demonstrating high specificity of this FLL. Overall, our results suggest a robust use for this novel FLL probe to increase our understanding of CNS-peripheral DAT regulation mechanisms underlying health and disease. This research is funded by the National Institutes of Health (NIH) – National Institute on Drug Abuse (NIDA) - Intramural Research Program.

Design, synthesis, and characterization of a novel, 4-[2-(diphenylmethoxy)ethyl]-1-benzyl piperidine-based, dopamine transporter photoaffinity label

Synthesis and biological evaluation of 18 F-labelled deuterated tropane derivatives as dopamine transporter probes

Characterization of Novel Pyrovalerone Analogs as Potential Dopamine Transporter Irreversible Ligands

Modifications to 1-(4-(2-Bis(4-fluorophenyl)methyl)sulfinyl)alkyl Alicyclic Amines That Improve Metabolic Stability and Retain an Atypical DAT Inhibitor Profile

Synthesis and initial evaluation of radioiodine-labelled deuterated tropane derivatives targeting dopamine transporter

Fluorescently Labelled Ligand Allow Detection of DAT in Human and Mouse Peripheral Blood Monocytes by Flow Cytometry

Synthesis and Evaluation of 18F-Labeled Phenylpiperazine-like Dopamine D3 Receptor Radioligands for Positron Emission Tomography Imaging

Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter

(S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-[125I]iodo- 2-methoxybenzamide hydrochloride, a new selective radioligand for dopamine D-2 receptors

Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents

Ligand Selectivity among the Dopamine and Serotonin Transporters Specified by the Forward Binding Reaction

Highly Efficient Radiosynthesis and Biological Evaluation of [18 F]Safinamide, a Radiolabelled Anti-Parkinsonian Drug for Positron Emission Tomography Imaging.

Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters

Cryo-EM structure of the dopamine transporter with a novel atypical non-competitive inhibitor bound to the orthosteric site

Structure-Based Discovery of a Novel Allosteric Inhibitor against Human Dopamine Transporter

Design, Synthesis, and Evaluation of Indolebutylamines As a Novel Class of Selective Dopamine D3 Receptor Ligands.

In vitro characterization of [125I]HY-3-24, a selective ligand for the dopamine D3 receptor

Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine Receptor

Synthesis and Fluoro-Radiolabelling of Dopamine D_2 Receptor Imaging Agent ~(18)F-FSABZM

Dopamine reuptake and inhibitory mechanisms in human dopamine transporter

Design, Synthesis, and Evaluation of Thienodiazepine Derivatives as Positron Emission Tomography Imaging Probes for Bromodomain and Extra-Terminal Domain Family Proteins